Direct Acting Antivirals for Hepatitis C (HCV) — Coverage Criteria
Customize your policy alerts
Sign up for all Alaska Medicaid policy alerts
Know when Alaska Medicaid releases new policies or updates existing guidance.
Monitor payer policy activity
Prior authorization and quantity limit policy for FDA‑approved direct acting antiviral (DAA) medications for treatment of chronic hepatitis C virus (HCV) infection for Alaska Medicaid members, including approval criteria, authorized regimens, and renewal requirements.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.